MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding MiNK Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 17 | 19 | +2 |
| Shares | 63.0K | 61.9K | −1.05K (−1.7%) |
| Value | $544.2K | $460.8K | −$83.4K (−15.3%) |
New holders (3)
Institutions that held MiNK Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Total Investment Management Inc | 500 | $3.69K | 0.00% |
| Raymond James Financial Inc | 32 | $236 | 0.00% |
| Key Financial Inc | 4 | $30 | 0.00% |
Sold out (1)
Institutions that held MiNK Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Tower Research Capital LLC (TRC) | 172 | $1.49K |